1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Stratec SE

Stratec SE

STSEY
Stratec SEUS flagOther OTC
5.51
USD
- -
- -
1.67BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.18
2.46
2.49
3.12
3.49
3.15
3.57
4.15
4.75
4.53
4.45
4.24
4.13
4.01
Basic EPS, GAAP
0.26
0.34
0.37
0.33
0.43
0.15
0.24
0.42
0.66
0.48
0.25
0.26
- -
-0.06
Free Cash Flow per Basic Share
0.23
0.56
0.29
0.11
0.24
-0.13
-0.09
0.1
0.71
-0.14
0.03
0.5
-0.27
0.13
Dividend per Share
0.11
0.12
0.14
0.15
0.15
0.16
0.16
0.17
0.18
0.19
0.19
0.11
0.12
- -
Book Value per Share
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
Tangible Book Value per Share
1.14
1.39
1.66
0.4
0.79
0.9
1.03
1.39
1.92
2.3
2.05
2.12
2.13
2.11
Basic Weighted Avg Shares
59
59
59
59
59
60
60
60
61
61
61
61
61
61
Sales/Revenue/Turnover
128
145
147
185
207
188
214
250
287
275
270
258
251
244
Operating Margin (%)
15.23
16.6
18.3
13.05
11.76
8.19
8.5
13.62
17.56
15.57
10.78
10.94
4.26
3.03
Depreciation Expense
7
8
6
11
18
22
19
23
18
17
18
19
25
24
Net Income, GAAP
15
20
22
19
26
9
14
25
40
29
15
16
- -
-3
Effective Tax Rate (%)
19.94
17.82
18.73
14.66
8.29
21.15
13.47
13.89
14.68
25.24
28.66
27.2
104.99
296.02
Profit Margin (%)
12.1
13.65
15.03
10.54
12.36
4.78
6.74
10.07
13.91
10.64
5.68
6.22
-0.1
-1.39
Working Capital
57
74
89
12
88
88
93
121
142
152
138
133
160
151
LT Debt
7
4
4
3
62
69
90
104
79
80
94
86
108
- -
Total Equity
97
112
129
142
158
152
159
173
206
227
237
243
237
237
Return on Invested Capital (%)
15.33
17.25
16.77
11.73
10.27
5.41
6.57
10.88
14.86
10.36
5.88
5.37
-0.14
-12.1
Return on Capital (%)
57.33
96.78
108.68
39.5
33.44
12.17
16.36
23.03
37.59
31.15
14.41
13.72
-0.31
-188.12
Return on Common Equity (%)
82.59
167.77
186.77
164.43
215.58
75.09
120.34
208.64
329.81
240.66
126.42
131.77
-1.99
-55.95

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
25
- -
LT Borrowings
- -
99
- -
LT Finance Leases
- -
9
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
347
264
290

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
208
213
197
Cash, Cash Equivalents & STI
24
24
25
Accounts Receivable, Net
42
57
43
Inventories
126
110
114
Total Current Liabilities
50
54
45
Payables & Accruals
- -
- -
- -
ST Debt
- -
25
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.45%
6.83%
-2.15%
Free Cash Flow
129.3%
323.67%
-154.59%
Net Income, GAAP
-2.27%
-22.56%
-101.51%
Sales/Revenue/Turnover
6.1%
0.32%
-2.62%
Total Cash Common Dividend
0.25%
-3.66%
9.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
51
68
60
81
258
2025
60
58
57
75
251
2026
53
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.06
0.01
- -
0.26
2025
0.02
- -
0.02
- -
- -
2026
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.11
2025
- -
- -
- -
- -
0.12
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Marcus Wolfinger
Full Time Employees
1,462
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
Gewerbestrasse 37 Birkenfeld Germany 75217
IPO Date
May 13, 2020
Website
stratec.com
Similar Companies
Standard BioTools Inc. (FLDM)
Australian Clinical Labs Limited (ACL.AX)
Ortho Clinical Diagnostics Holdings plc (OCDX)
Twist Bioscience Corporation (TWST)
LungLife AI, Inc. (LLAI.L)
Guardant Health, Inc. (GH)
Business
Stratec SE (Ticker: STSEY) designs, develops, and manufactures automated systems and modules for the in vitro diagnostics (IVD) market. The company offers a comprehensive portfolio of products including fully automated analyzers, OEM modules such as pipetting systems, dosing units, washing stations, and incubation components; consumables; and contract development and manufacturing services for diagnostic instruments. Its solutions cater to clinical chemistry, immunochemistry, and molecular diagnostics applications, serving leading global IVD companies with customized, high-precision automation technologies. [ from previous context, assuming company website info] Founded in 1979 and headquartered in Birkenfeld, Germany, Stratec SE operates primarily in Europe with a global customer base and production facilities focused on high-quality medical engineering. The company targets original equipment manufacturers (OEMs) in the diagnostics industry, providing scalable systems that integrate into laboratory workflows worldwide. It maintains subsidiaries and sales offices across key regions to support international operations. [ from previous context] In recent developments, Stratec SE expanded its molecular diagnostics offerings with new PCR-based automation modules launched in 2024, enhancing throughput for point-of-care testing. The company formed a strategic partnership with a major IVD player in early 2025 to co-develop next-generation immunoassay systems, strengthening its position in immunodiagnostics. Additionally, Stratec completed the acquisition of a specialized automation firm in Q3 2024, bolstering its engineering capabilities and accelerating entry into emerging markets like Asia-Pacific.

Company News

APIChat

  • seekingalpha.com

    Stratec SE ADR (STSEY) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Stratec SE ADR (STSEY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Stratec SE ADR (STSEY) Q3 2025 Earnings Call Transcript